Tamoxifen as an effective treatment for refractory mania: a case report
DOI:
https://doi.org/10.46932/sfjdv4n5-023Keywords:
bipolar disorder, mania, tamoxifen, Protein Kinase C (PKC), case reportAbstract
Tamoxifen is a medication that acts as a selective estrogen receptor modulator (SERM) by inhibiting protein kinase C (PKC). It has various effects on different tissues in the body, depending on whether the tissue expresses estrogen receptors. For instance, it can reduce inflammation and neuronal excitability. Several studies have shown that tamoxifen could be effective in treating refractory mania, a type of mania that has shown resistance to mood stabilizers and other treatments. The rationale for its use could be explained by the fact that PKC is an enzyme that seemingly plays a significant role in the genesis of mania. We present the case of a 43-year-old female patient with bipolar disorder, who has had 43 previous hospitalizations and has undergone multiple treatments. Management with tamoxifen was initiated to control the manic episode.
References
Abé, C., Liberg, B., Klahn, A. L., Petrovic, P., & Landén, M. (2023). Mania-related effects on structural brain changes in bipolar disorder – a narrative review of the evidence. En Molecular Psychiatry. Springer Nature. https://doi.org/10.1038/s41380-023-02073-4
Abrial, E., Etievant, A., Bétry, C., Scarna, H., Lucas, G., Haddjeri, N., & Lambás-Señas, L. (2013). Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 43, 40–48. https://doi.org/10.1016/j.pnpbp.2012.11.015
Aldana-López, J. A., & Medina-Dávalos, R. (2016). Experiencia con el uso de inhibidor de la proteína quinasa C (tamoxifeno) en la manía: Reporte de caso. Salud Jalisco, 3(1), 54–59. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=77099
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425596
Amrollahi, Z., Rezaei, F., Salehi, B., Modabbernia, A. H., Maroufi, A., Esfandiari, G. R., Naderi, M., Ghebleh, F., Ahmadi-Abhari, S. A., Sadeghi, M., Tabrizi, M., & Akhondzadeh, S. (2011). Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of Affective Disorders, 129(1–3), 327–331. https://doi.org/10.1016/j.jad.2010.08.015
Buijs, C., Willemse, P. H. B., de Vries, E. G. E., Ten Hoor, K. A., Boezen, H. M., Hollema, H., & Mourits, M. J. E. (2009). Effect of Tamoxifen on the Endometrium and the Menstrual Cycle of Premenopausal Breast Cancer Patients. International Journal of Gynecological Cancer, 19(4), 667–681. https://doi.org/10.1111/IGC.0b013e3181a47cbe
Chalas, E., Costantino, J. P., Wickerham, D. L., Wolmark, N., Lewis, G. C., Bergman, C., & Runowicz, C. D. (2005). Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. American Journal of Obstetrics and Gynecology, 192(4), 1230–1237. https://doi.org/10.1016/j.ajog.2004.12.083
Dal-Pont, G. C., Resende, W. R., Bianchini, G., Gava, F. F., Peterle, B. R., Trajano, K. S., Varela, R. B., Quevedo, J., & Valvassori, S. S. (2019). Tamoxifen has an anti-manic effect but not protect the brain against oxidative stress in an animal model of mania induced by ouabain. Journal of Psychiatric Research, 113(October 2018), 181–189. https://doi.org/10.1016/j.jpsychires.2019.03.020
Fallah, E., Arman, S., Najafi, M., & Shayegh, B. (2016). Effect of tamoxifen and lithium on treatment of acute mania symptoms in children and adolescents. Iranian Journal of Child Neurology, 10(2), 16–25.
Hong, Y., Huang, W., Cao, D., Xu, J., Wei, H., Zhang, J., & Wang, L. (2022). A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years. Psychopharmacology, 239(10), 3367–3375. https://doi.org/10.1007/s00213-022-06230-5
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Nomura, I., Hatano, M., & Iwata, N. (2022). Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry, 27(2), 1136–1144. https://doi.org/10.1038/s41380-021-01334-4
Ledezma-Acevedo, J. A., González-Méndez, J. G., & Calderón-Rivera, D. (2020). Utilidad del uso de Tamoxifeno en cuadro agudo de manía en Trastorno Bipolar. Salud Jalisco, 6(Esp), 48–56. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=92405
Palacios, J., Yildiz, A., Young, A. H., & Taylor, M. J. (2019). Tamoxifen for bipolar disorder: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(2), 177–184. https://doi.org/10.1177/0269881118822167
Thanvi, V. (2022). Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms. Case Reports in Psychiatry, 2022, 1–4. https://doi.org/10.1155/2022/3684181
Valvassori, S. S., Dal-Pont, G. C., Resende, W. R., Varela, R. B., Peterle, B. R., Gava, F. F., Mina, F. G., Cararo, J. H., Carvalho, A. F., & Quevedo, J. (2017). Lithium and Tamoxifen Modulate Behavior and Protein Kinase C Activity in the Animal Model of Mania Induced by Ouabain. International Journal of Neuropsychopharmacology, 20(11), 877–885. https://doi.org/10.1093/ijnp/pyx049
Vieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018a). Bipolar disorders. Nature Reviews Disease Primers, 4(1), 1–16. https://doi.org/10.1038/nrdp.2018.8
Vieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018b). Bipolar disorders. Nature Reviews Disease Primers, 4(1), 18008. https://doi.org/10.1038/nrdp.2018.8
Wolf, D. M., & Jordan, V. C. (1994). The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Research and Treatment, 31(1), 129–138. https://doi.org/10.1007/BF00689683
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O’Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., … Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609
Yildiz, A., Guleryuz, S., Ankerst, D. P., Öngür, D., & Renshaw, P. F. (2008). Protein Kinase C Inhibition in the Treatment of Mania. Archives of General Psychiatry, 65(3), 255. https://doi.org/10.1001/archgenpsychiatry.2007.43
Zarate, C. A., Singh, J. B., Carlson, P. J., Quiroz, J., Jolkovsky, L., Luckenbaugh, D. A., & Manji, H. K. (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disorders, 9(6), 561–570. https://doi.org/10.1111/j.1399-5618.2007.00530.x
Downloads
Published
How to Cite
Issue
Section
